Researchers from the Life Sciences Research Unit (LSRU) of the University of Luxembourg have developed a computer model that simulates the metabolism of cancer cells. They used the programme to investigate how combinations of drugs could be used more effectively to stop tumour growth. The biologists now published their findings in the scientific journal EBioMedicine of the prestigious Lancet group. …
Backed by Dana-Farber research, FDA approves new drug combination for treating advanced kidney cancer
Source: dana-farber.org From: Redington Life Sciences News An immunotherapy drug combination whose clinical testing was co-led by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, has become a standard first-line therapy for patients with metastatic kidney cancer. The drug combination of the immunotherapy drug avelumab (BAVENCIO) plus axitinib (INLYTA), a VEGF targeted agent, was approved today by the U.S. Food …
Medicare recipients may pay more for generics than their brand-name counterparts, study finds
Source: Vanderbilt University Medical Center From: news-medical.net Medicare Part D enrollees may pay more out of pocket for high-priced specialty generic drugs than their brand-name counterparts, according to new research by health policy experts at Vanderbilt University Medical Center and the University of North Carolina at Chapel Hill. Researchers examined differences in brand-name and generic or biosimilar drug prices, formulary …
Nearly all women are confronted with health problems after breast cancer
By: Martine Van Hillegersberg, University of Twente From: medicalxpress.com Nearly all women who have been treated for non-metastatic breast cancer suffer from health problems after primary treatment. The problems reported by women include fatigue, tingling in the hands and feet (neuropathy), and memory and concentration problems. For two-third of these problems, healthcare services were sought. Chemotherapy was the treatment responsible …
Dignitana receives FDA clearance for DigniCap Delta scalp cooling system
From: PR Newswire Clinically superior next generation device reduces hair loss for cancer patients Dignitana AB, world leader in medical scalp cooling technology, announced today that the United States Food and Drug Administration has cleared DigniCap Delta® for use by U.S. health care providers. The new device is the fourth generation of The DigniCap® Scalp Cooling System and is indicated to prevent …
One-Way Texting: No Help with Breast Cancer Pill Taking, But…
Maybe Two-Way Texting Will Do the Job! By: Nick Mulcahy From: medscape.com Can American breast cancer clinicians solve the thorny problem of adherence to aromatase inhibitors (AIs) by text messaging their patients? The communications innovation, first conceived in 1984 by a Finnish engineer and implemented in 1992 by a British tech employee, is now part of daily life, which, for …
First Cost-Effectiveness Study of Multi-Gene Panel Sequencing in Advanced Non-Small Cell Lung Cancer Shows Moderate Cost-Effectiveness, Exposes Crucial Practice Gap
From: PR Newswire The results of the first economic modeling study to estimate the cost-effectiveness of “multi-gene panel sequencing” (MGPS) as compared to standard-of-care, single-gene tests for patients with advanced non-small cell lung cancer (aNSCLC) show that the MGPS tests are moderately cost-effective but could deliver more value if patients with test results identifying actionable genetic mutations consistently received genetically guided …
Genetic accelerators reveal themselves
The DNA of two people differs in millions of places. But which of those variants also have an actual effect on how our bodies function? Researchers from the Netherlands Cancer Institute have developed a technique that allows them to see which changes in the genetic code affect the activity of genes and, therefore, how we function. They publish their findings …
Savvy Cooperative Opportunity: Metastatic or Early Stage Breast, Multiple Myeloma, Melanoma, Prostate, Lung, Colorectal, or Pediatric Cancer Patients or Family Caregivers
Savvy Cooperative is calling cancer patients and caregivers for a unique opportunity! We are working with a design-centered research firm recruiting for a unique project. We are looking for metastatic or early stage breast, multiple myeloma, melanoma, prostate, lung, colorectal, or pediatric cancer patients or family caregivers who can be described as in one of the following parts of their …
New Patient Resource from NCCN Helps People with Bladder Cancer Make Informed Treatment Decisions
New NCCN Guidelines for Patients: Bladder Cancer explains the lengthy surveillance process that follows active treatment for the sixth most-common cancer in the United States. The treatment landscape for bladder cancer has changed dramatically over the past few years. Despite being the sixth most common cancer in the United States, and fourth most common for men—impacting an estimated 81,000 Americans …